Semaglutide
Compounded GLP-1 Receptor Agonist
A GLP-1 receptor agonist that mimics your body's natural hunger-regulating hormone. Semaglutide reduces appetite, slows gastric emptying, and supports steady, sustainable weight loss when paired with a healthy lifestyle. Available after a licensed-provider evaluation by an independent network of US-licensed providers, with the medication dispensed by a US-licensed compounding pharmacy.
Starting from $99 your first month
Then $169/mo all doses | Cancel Anytime | 3-Month & 6-Month Bundles Available
Frequency
Once Weekly
Rx Required
Yes, Prescribed Online
Pharmacy
US-Registered
Shipping
Free & Discreet
Semaglutide at a Glance
How much does compounded semaglutide cost per month? Through Madison Meds, compounded semaglutide starts at $99 your first month, then $169 per month all doses, all-inclusive. There is no separate subscription fee, licensed-provider evaluation charge, or shipping charge on top of the monthly price.
Who is eligible for compounded semaglutide? Adults with weight-related health considerations may be candidates. Eligibility is confirmed after a licensed-provider evaluation by an independent network of US-licensed providers who review your full health profile.
What is included in the monthly price? Licensed-provider evaluation, the compounded semaglutide medication dispensed by a US-licensed compounding pharmacy, ongoing telehealth support, and free discreet shipping. Cancel anytime.
What is compounded semaglutide? Compounded semaglutide is the same active pharmaceutical ingredient found in FDA-approved brand-name semaglutide products, dispensed by a US-licensed compounding pharmacy after a licensed-provider evaluation. It is prepared to the specifications set by the prescriber for the individual patient. Availability, formulations, and pricing differ from brand-name products.
How Semaglutide Works
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It works by mimicking the natural GLP-1 hormone your gut produces after eating. This hormone signals your brain that you're full, regulates insulin, and slows digestion, all of which naturally reduce how much you eat.
When administered as a weekly injection, Semaglutide activates GLP-1 receptors in the hypothalamus and brainstem, the brain areas that control hunger and satiety. This leads to reduced appetite, fewer cravings, and a natural decrease in caloric intake without the feeling of deprivation.
Semaglutide also slows gastric emptying, which means food stays in your stomach longer after meals. This extends the feeling of fullness and reduces the urge to snack between meals. Combined with improved insulin sensitivity and enhanced fat metabolism, the result is steady, sustainable weight loss.
What Semaglutide Can Do for You
Appetite Reduction
Significantly reduces hunger and cravings by targeting appetite-regulating centers in the brain, making it easier to eat less naturally.
Sustainable Weight Loss
Clinical studies show an average of 15% body weight reduction over 68 weeks when combined with lifestyle changes.
Improved Metabolic Health
Supports healthier blood sugar levels, cholesterol, blood pressure, and triglycerides, reducing cardiovascular risk factors.
Once-Weekly Convenience
A single subcutaneous injection per week, no daily pills or complicated routines. Simple, quick, and easy to maintain.
Provider-Reviewed
Reviewed and prescribed by an independent network of US-licensed providers. Dosing is gradually titrated to minimize side effects and support consistent results. Individual results vary.
Increased Energy
Many patients report higher energy levels and improved overall wellbeing as their weight decreases and metabolic function improves.
What to Expect
Week 1–4: Getting Started
You'll begin with a low starter dose. Many patients notice a reduction in appetite within the first 1–2 weeks. Some may experience mild nausea as the body adjusts, this typically subsides.
Week 4–8: Building Momentum
Your dose is gradually increased based on your response and tolerability. Appetite suppression becomes more consistent, and most patients begin seeing noticeable weight loss during this period.
Week 8+: Sustained Progress
At your target maintenance dose, hunger and cravings are well managed. Weight loss continues steadily when combined with balanced nutrition and regular activity. Your provider monitors your progress and adjusts as needed.
Compounded Semaglutide vs. Brand-Name
What "compounded" means. Compounding is the practice of preparing a medication specifically for an individual patient based on a valid prescription. Compounding pharmacies have operated legally in the United States for decades and are regulated at the state level by pharmacy boards, with additional federal standards including USP 797 for sterile preparations.
The FDA-approval distinction. Compounded semaglutide is not FDA-approved as a finished drug product. The active pharmaceutical ingredient is FDA-regulated, but the compounded formulation as a finished product has not gone through the FDA's new drug application process. This is an important distinction to understand before starting treatment. The pharmacies Madison Meds partners with are US-licensed compounding pharmacies operating under state pharmacy board oversight, but the compounded product itself does not carry FDA approval.
Why compounding is legal and regulated. Compounding is explicitly permitted under federal law (sections 503A and 503B of the Food, Drug & Cosmetic Act) under specific conditions. State-licensed pharmacies may compound medications for individual patients based on a valid prescription. Madison Meds partners only with US-licensed compounding pharmacies that meet USP 797 sterile compounding standards.
For full transparency about the compounded formulation we work with, please review our Compounded Medication Disclosure.
Semaglutide Cost in 2026: What Every Channel Charges
Bottom line: Through Madison Meds, compounded semaglutide is priced from $99 your first month, then $169 per month all doses, all-inclusive, compared to brand-name Wegovy at $1,349.02 per month or Ozempic at approximately $998 per month retail. Compare 2026 pricing across every channel below.
2026 Semaglutide Cost by Channel
The short answer. In 2026, semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) is available at prices ranging from about $99 per month to over $1,300 per month depending on the channel. Brand-name Wegovy carries a 2026 list price of $1,349.02 per month (Wegovy official), brand-name Ozempic sits at roughly $998 per month at retail (Noom), and oral Rybelsus lists around $1,248 per month at retail (GoodRx). Novo Nordisk's NovoCare Pharmacy self-pay program offers Wegovy from $199 to $399 per month and Ozempic from $349 to $499 per month depending on dose and eligibility (NovoCare). Commercially insured patients using the Wegovy savings offer can pay as little as $25 per month (Wegovy Savings). Through Madison Meds, compounded semaglutide is available starting from $99 your first month, then $169 per month all doses, after a licensed-provider evaluation, with the medication dispensed by a US-licensed compounding pharmacy.
| Channel | 2026 Monthly Cost | What's Included | Eligibility |
|---|---|---|---|
| Madison Meds compounded semaglutide | From $99 first month, then $169/mo all doses | Licensed-provider evaluation, medication, ongoing telehealth support, free discreet shipping | Adults with weight-related health considerations; determined after licensed-provider evaluation |
| Wegovy (brand, retail list) | $1,349.02/mo (source) | Medication only | FDA-approved for chronic weight management; provider prescription required |
| Ozempic (brand, retail list) | ~$998/mo (source) | Medication only | FDA-approved for type 2 diabetes; provider prescription required |
| Rybelsus (oral semaglutide, brand retail) | ~$1,248/mo (source) | Medication only; daily tablet | FDA-approved for type 2 diabetes; provider prescription required |
| NovoCare Wegovy pen intro (0.25/0.5 mg, first 2 fills) | $199/mo (source) | Medication only; introductory pricing | Cash-pay patients; first 2 fills only, through Dec 31, 2026 |
| NovoCare Wegovy pen standard (all doses 0.25–2.4 mg) | $349/mo (source) | Medication only | Cash-pay patients after intro period |
| NovoCare Wegovy tablets (1.5 mg + 4 mg) | $149/mo (4 mg through Aug 31, 2026) (source) | Medication only; oral tablet format | Cash-pay patients; 4 mg promo, then $199/mo |
| NovoCare Ozempic (0.25/0.5/1 mg) | $349/mo (source) | Medication only | Cash-pay patients; T2D diagnosis typically expected |
| Wegovy with commercial insurance + savings offer | As low as $25/mo, up to $100/mo max (source) | Medication only | Commercial insurance that covers Wegovy; excludes Medicare, Medicaid, VA, TRICARE |
| Compounded semaglutide (market floor across telehealth providers) | From $99 first month advertised (source) Market-floor pricing typically reflects introductory rates, low-dose starter programs, subscription-locked plans, or bulk multi-month prepay commitments, and often steps up after the first month. | Varies by provider; commonly medication only. Provider evaluation, ongoing telehealth support, and shipping may be billed separately or require a paid subscription. | Varies; typically requires online evaluation by a licensed provider |
| Medicare Bridge Program (July 2026–Dec 2027) for Wegovy | $50/mo flat (source) | Medication only; Wegovy pen or pill | Medicare beneficiaries with BMI 27+ and obesity-related comorbidity |
Brand Semaglutide: Ozempic, Wegovy, and Rybelsus Pricing
Novo Nordisk sells three brand-name semaglutide products in the US, each with a different labeled indication and price point. Wegovy is the FDA-approved chronic weight management version, listing at $1,349.02 per month at retail cash price in 2026 (Wegovy.com). Ozempic is FDA-approved for type 2 diabetes at approximately $998 per month retail (Noom). Rybelsus, the oral tablet version of semaglutide indicated for type 2 diabetes, runs around $1,248 per month at retail (GoodRx). All three carry the same active molecule but differ in delivery method, labeled use, and price.
NovoCare Pharmacy Self-Pay: The Manufacturer Cash Program
Novo Nordisk operates NovoCare Pharmacy for cash-pay Wegovy and Ozempic. Wegovy pen introductory pricing is $199 per month for the first two fills at 0.25 mg or 0.5 mg starter doses, running through December 31, 2026 (NovoCare). After the intro period, Wegovy pens at any dose from 0.25 mg through 2.4 mg cost $349 per month, and the higher-dose HD 7.2 mg pen is $399 per month. Wegovy tablets offer another entry point: 1.5 mg and 4 mg cost $149 per month (with 4 mg promo running through August 31, 2026, then $199), and higher-dose 9 mg and 25 mg tablets are $299 per month. Ozempic self-pay through NovoCare is $349 per month for 0.25, 0.5, or 1 mg doses and $499 per month for 2 mg.
Savings Offers and Insurance Reality
The Wegovy Savings Offer brings monthly costs as low as $25 per month for commercially insured patients whose plan covers Wegovy, with a per-fill maximum of $100 (Wegovy Savings). Novo Nordisk savings offers exclude Medicare, Medicaid, VA, and TRICARE beneficiaries and expire December 31, 2026. Most commercial insurance plans require prior authorization for Wegovy and often deny coverage, particularly when the indication is weight management rather than a diagnosed metabolic condition. Medicare does not cover GLP-1 medications for weight loss under Part D, although the Medicare Bridge Program launched July 1, 2026 provides $50 per month for Wegovy pen, Wegovy pill, Zepbound KwikPen, and Foundayo for eligible Medicare beneficiaries with BMI 27 and above and an obesity-related comorbidity, running through December 31, 2027 (PeptideDeck). For most patients outside these narrow paths, insurance is not a reliable option.
How Madison Meds Pricing Works
Through Madison Meds, compounded semaglutide is available starting from $99 your first month, then $169 per month for all doses, after a licensed-provider evaluation by an independent network of US-licensed providers, with the medication dispensed by a US-licensed compounding pharmacy. Pricing is all-inclusive: the online evaluation, the medication, ongoing telehealth support with your provider, and free discreet shipping are all bundled into the monthly price. There are no separate consultation fees, no membership add-ons, and no shipping charges. If a licensed provider determines semaglutide is not appropriate for your health profile, you are not charged for the evaluation. Compounded semaglutide is not FDA-approved as a finished drug product; it is prepared per patient prescription by a US-licensed compounding pharmacy. Outcomes are individual, and results vary from person to person.
Who Semaglutide Is For
Who qualifies: Adults with weight-related health considerations may be candidates for compounded semaglutide. Final eligibility is determined after a licensed-provider evaluation by an independent network of US-licensed providers.
Eligibility & Candidate Criteria
Who is typically a good candidate. Semaglutide may be considered for eligible adults with weight-related health considerations, such as high blood pressure, elevated blood sugar, or dyslipidemia. People who have struggled to maintain weight loss through lifestyle changes alone are often the population where semaglutide may be appropriate after a licensed-provider evaluation.
The strongest responses tend to come from people who are consistent with weekly dosing, follow through on lifestyle changes alongside medication, and work with a provider to adjust dosing at the right pace.
Who may not be a good fit. Semaglutide is not appropriate for everyone. People with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) should not take it. It is not recommended during pregnancy or while breastfeeding. People with a history of pancreatitis or significant gastrointestinal conditions may need an alternative approach.
After a licensed-provider evaluation by an independent network of US-licensed providers, a provider will assess whether semaglutide may be appropriate based on your full health picture. If it is not, you will not be charged for the evaluation. Outcomes are individual, and results vary from person to person.
Side Effects & Drug Interactions
Understanding the full safety profile of semaglutide helps you make an informed decision and know what to watch for during treatment. This section is educational content, not medical advice. Please discuss your individual risk factors with a licensed provider.
Common side effects and how to manage them. The most frequently reported side effects of semaglutide are gastrointestinal and are typically mild to moderate:
- Nausea is the most common, especially early in treatment and after dose increases. It typically fades as your body adjusts. Tips: inject at night, eat smaller meals, avoid fatty or heavily processed foods around injection day.
- Constipation is common and often underreported. Staying well hydrated, eating adequate fiber, and gentle movement help.
- Diarrhea occurs in some people, usually early in treatment, and typically resolves without intervention.
- Vomiting can occur, particularly with large or rich meals. Eat slowly and stop when full.
- Stomach pain or bloating is generally mild and transient.
- Fatigue is occasionally reported, especially in early weeks.
When to contact your provider. Reach out promptly if you experience persistent or severe abdominal pain (especially radiating to the back), significant or persistent vomiting, signs of low blood sugar if you also take diabetes medications, a lump or swelling in your neck, hoarseness or difficulty swallowing, or signs of a serious allergic reaction.
Drug interactions worth noting. Semaglutide slows gastric emptying, which can affect absorption timing of oral medications including certain thyroid medications and oral contraceptives. Semaglutide used alongside insulin or insulin-stimulating medications may increase the risk of hypoglycemia. Provide a complete list of medications, supplements, and health conditions during your intake evaluation so any interactions can be flagged.
Boxed warning context. Semaglutide carries a boxed warning related to thyroid C-cell tumors observed in animal studies. The relevance of these findings to humans is not established, but semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2.
This is educational content, not medical advice. A licensed provider will review your full health history during your evaluation to assess whether semaglutide may be appropriate given your specific risk profile.
Important Safety Information
Compounded semaglutide is not FDA-approved as a finished drug product. It is prepared by a US-licensed compounding pharmacy under a prescription from an independent network of US-licensed providers. Side effects may include nausea, vomiting, diarrhea, constipation, and stomach pain, most are mild and decrease over time as dosing is titrated.
Semaglutide should not be used by individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Not recommended during pregnancy or breastfeeding. Always consult your healthcare provider to determine if this treatment is appropriate for you.
Ready to take the next step?
Complete a brief online evaluation to see if Semaglutide is right for you. A licensed provider will review your health profile and create a personalized plan.
FAQ